Biosimilars are “follow-on biologics,” products with properties similar to existing innovator biologics that are marketed after patent expiration. The development of biosimilars is on the rise as many innovator biologics, primarily monoclonal antibodies, approach patent expiration. Driven by the reduced cost of these life-changing medicines, market demand for biosimilars is expected to grow substantially, creating a unique opportunity for biosimilar clinical development.
The PPD Biosimilar Investigator Network is a growing community of investigators participating in biosimilars clinical trials worldwide. Join the network and realize these important benefits: